Paclitaxel: a promising addition to the antineoplastic armamentarium


    loading  Checking for direct PDF access through Ovid

Abstract

IN BRIEFPaclitaxel has antineoplastic activity in advanced forms of ovarian and breast cancer that are unresponsive to standard therapy.The drug has been associated with serious toxicity, including hypersensitivity reactions, neutropenia and neuropathy. Currently, premedication regimens limit the occurrence of hypersensitivity, and haematopoietic support may reduce the risk of neutropenia. However, other adverse effects such as neuropathy then become doselimiting.The optimal dose and schedule for administering paclitaxel, and the effects of the drug on patient survival and quality of life, have not yet been determined.

    loading  Loading Related Articles